← Back to Search

Other

Probenecid for Opioid Withdrawal

Phase 2

Recruiting

Led By Lori Montgomery, MD

Research Sponsored by University of Calgary

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Capable of providing informed consent

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 years

Awards & highlights

Study Summary

This trial looks to help people suffering from opioid withdrawal by using an existing drug, probenecid, to block a protein in the spinal cord responsible for withdrawal symptoms.

Who is the study for?

Adults over 18 with chronic pain, currently on daily opioid medication and planning to reduce their dose. They must have a kidney function test (GFR) above 50 mL/min and be able to give informed consent. The trial is not suitable for those who cannot voluntarily decrease their opioid use or have other health issues that the study doesn't list.Check my eligibility

What is being tested?

The trial tests Probenecid's effectiveness in easing symptoms of opioid withdrawal in patients dependent on opioids due to chronic pain management. It explores whether this already approved drug can block certain proteins involved in withdrawal symptoms.See study design

What are the potential side effects?

While specific side effects are not listed here, Probenecid is generally considered safe but could potentially cause allergic reactions, gastrointestinal discomfort, headache, dizziness, or increase the risk of gout.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I can understand and agree to the study's details.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

To evaluate acceptability of oral probenecid in patients undergoing voluntary opioid tapering

To evaluate safety of oral probenecid in patients undergoing voluntary

To evaluate tolerability of oral probenecid in patients undergoing voluntary opioid tapering

Secondary outcome measures

To evaluate the feasibility of treatment with probenecid in a patient-directed opioid tapering protocol, in the setting of an interdisciplinary pain clinic

To evaluate whether Panx1 gene variants correlate with opioid withdrawal severity and response to probenecid by collecting salivary samples and performing DNA extraction in a small cohort.

Trial Design

3Treatment groups

Active Control

Placebo Group

Group I: Probenecid 500 mg PO BIDActive Control1 Intervention

Probenecid 500 mg X 1 PO BID and Placebo X 1 PO BID

Group II: Probenecid 1000 mg PO BIDActive Control1 Intervention

Probenecid 500mg X 2 PO BID

Group III: Placebo PO BIDPlacebo Group1 Intervention

Placebo X 2 PO BID

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of CalgaryLead Sponsor

795 Previous Clinical Trials

870,085 Total Patients Enrolled

6 Trials studying Chronic Pain

596 Patients Enrolled for Chronic Pain

Lori Montgomery, MDPrincipal InvestigatorUniversity of Calgary

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there opportunities for recruitment into this clinical experiment?

"As indicated on the clinicaltrials.gov website, currently this medical trial is searching for suitable applicants. This investigation was initially posted on October 31st 2023 and recently updated on November 29th 2023."

Answered by AI

For what size of a population is this clinical trial recruiting?

"Affirmative. Clinicaltrials.gov attests to the fact that this experiment is actively seeking participants, which was first revealed on October 31st 2023 and recently updated on November 29th 2023. 40 volunteers are needed from 1 site for successful data collection."

Answered by AI

Does this clinical trial allow for patient participation from individuals aged 25 or older?

"To be eligible for this study, potential patients must fall between the ages of 18 and 80. 118 clinical trials are available to younger participants while 592 exist for those over 65 years old."

Answered by AI

What criteria must an individual meet in order to be eligible for this research endeavor?

"The purpose of the trial is to recruit 40 adults with chronic pain between 18 and 80 years old. Furthermore, they must be taking opioids daily and willing to reduce their intake in the 12-week period; have a GFR higher than 50 mL/min; and provide informed consent prior to enrolment."

Answered by AI

Are there any deleterious effects to taking Probenecid 500 mg orally twice daily?

"With Phase 2 clinical data confirming some degree of safety, our team assigned Probenecid 500 mg PO BID a score of 2 on the 1-3 scale. Efficacy has yet to be ascertained."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Novel Use of Probenecid to Alleviate Symptoms of Opioid Withdrawal

2023. "Novel Use of Probenecid to Alleviate Symptoms of Opioid Withdrawal". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04939623.

All > American Chronic Pain > Chronic Pain